XML 98 R67.htm IDEA: XBRL DOCUMENT
v3.23.1

RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | 28 Months Ended |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2022 | Jan. 31, 2022 | Feb. 28, 2021 | Nov. 30, 2020 | Mar. 31, 2019 | Dec. 31, 2018 | Jun. 30, 2018 | Dec. 31, 2022 | Dec. 31, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | Jun. 30, 2020
Research and development |  |  |  |  |  |  |  | $ 6,837,133 | $ 11,716,718 |  |  |
License cost |  |  |  |  |  |  |  | 40,000 | 60,000 |  |  |
Proceeds from convertible debt | $ 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  | 4,983,556 | 5,653,725 |  |  |
License Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  | 632,004 |  |  |
University of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | 14,000 | 243,000 |  |  |
Yi Xin Zhen Duan Jishu Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  | 670,000 |  |  |
Product sales |  |  |  |  |  |  |  |  | 38,000 |  |  |
Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  | 632,000 |  |  |
STA Pharmaceutical Co Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | 9,000 | 3,200,000 |  |  |
Upfront deposit |  |  |  |  |  |  |  |  |  |  | $ 1,100,000 |
Sponsored Research and License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | 164,000 | 325,000 |  |  |
License cost |  |  |  |  |  |  |  | 94,000 | 118,000 |  |  |
Minimum annual royalties |  |  |  |  |  |  |  | 0 | 0 |  |  |
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of research expenses |  |  | $ 2,700,000 |  | $ 693,000 |  |  |  |  |  |  |
Agreement term payment, description |  |  |  |  | In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $ |  |  |  |  |  |  |
Regulatory marketing approval, expenses |  |  |  |  | $ 300,000 |  |  |  |  |  |  |
Cumulative sales |  |  |  |  |  |  | $ 500,000,000 |  |  |  |  |
Licensed product net sale |  |  |  |  | 500,000,000 |  |  |  |  |  |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of research expenses |  |  |  |  |  |  |  |  |  | $ 830,000 |  |
Agreement term payment, description |  |  |  |  |  |  |  |  |  | In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. |  |
Research and development |  |  |  |  |  |  |  | 758,000 | 646,000 |  |  |
License cost |  |  |  |  |  |  |  | 2,000 | 28,000 |  |  |
Proceeds from convertible debt |  |  |  |  |  |  |  |  |  | $ 50,000 |  |
Patent costs |  |  |  |  |  |  |  |  |  | 200,000 |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member] |  |  |  |  |  |  |  |  |  |  |  |
Regulatory marketing approval, expenses |  |  |  |  |  |  | 5,000,000 |  |  |  |  |
Cumulative sales |  |  |  |  | 5,000,000 |  |  |  |  |  |  |
Regulatory marketing approval, expenses |  |  |  |  |  |  | 500,000 |  |  |  |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | 50,000 |  | 100,000 |  |  |  |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | 100,000 |  | 200,000 |  |  |  |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | 150,000 |  | 350,000 |  |  |  |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  | 500,000 |  |  |  |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | 50,000 |  | 100,000 |  |  |  |  |
Shortfall payments |  |  |  |  |  |  |  |  |  | 10,000 |  |
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  | 5,000,000 |  | $ 5,000,000 |  |  |  |  |
Shortfall payments |  |  |  |  |  |  |  |  |  | $ 50,000 |  |
License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
License cost |  |  |  |  |  |  |  | 338,000 | 0 |  |  |
Reimbursement of patent |  | $ 160,000 |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | Upfront Payment [Member] |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of patent |  | $ 150,000 |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | University of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  |  |  |  |  |  |  |  | $ 24,000
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  | 20,000 |  |  |  |  |  |  |
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  | $ 100,000 |  |  |  |  |  |  |
Research and development |  |  |  | $ 430,000 |  |  |  |  |  |  |  |
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |
Cumulative sales |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |
Licensed product net sale |  |  |  |  |  | 2,000,000 |  |  |  |  |  |
License cost |  |  |  |  |  |  |  | $ 0 | $ 2,000 |  |  |
Proceeds from convertible debt |  |  |  |  |  | $ 25,000 |  |  |  |  |  |
Agreement description |  |  |  |  |  | the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate |  |  |  |  |  |
Milestone payment for cumulative marketing expenses |  |  |  |  |  | $ 100,000 |  |  |  |  |  |
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member] | CE Mark [Member] |  |  |  |  |  |  |  |  |  |  |  |
Cumulative sales |  |  |  |  |  | 500,000 |  |  |  |  |  |
Licensed product net sale |  |  |  |  |  | 3,000,000 |  |  |  |  |  |
Milestone method revenue recognized |  |  |  |  |  | $ 100,000 |  |  |  |  |  |

X
- Definition Agreement description. + References No definition available. + Details
Name: | QLGN_AgreementDescription
Namespace Prefix: | QLGN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement term payment, description. + References No definition available. + Details
Name: | QLGN_AgreementTermPaymentDescription
Namespace Prefix: | QLGN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative sales. + References No definition available. + Details
Name: | QLGN_CumulativeSales
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License costs. + References No definition available. + Details
Name: | QLGN_LicenseCost
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone method revenue recognized. + References No definition available. + Details
Name: | QLGN_MilestoneMethodRevenueRecognized
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | QLGN_MilestonePayment
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment for cumulative marketing expenses. + References No definition available. + Details
Name: | QLGN_MilestonePaymentForCumulativeMarketingExpenses
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Patent costs. + References No definition available. + Details
Name: | QLGN_PatentCosts
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory marketing approval, expenses. + References No definition available. + Details
Name: | QLGN_RegulatoryMarketingApprovalExpenses
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory marketing approval expenses one. + References No definition available. + Details
Name: | QLGN_RegulatoryMarketingApprovalExpensesOne
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursement of patent. + References No definition available. + Details
Name: | QLGN_ReimbursementOfPatent
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursement of research expenses. + References No definition available. + Details
Name: | QLGN_ReimbursementOfResearchExpenses
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Shortfall payments. + References No definition available. + Details
Name: | QLGN_ShortfallPayments
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront license fee. + References No definition available. + Details
Name: | QLGN_UpfrontLicenseFee
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DepositAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_AdvancedCancerTherapeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=QLGN_CEMarkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |